Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
Ziegler AG, Achenbach P, Weiß A, Berner R, Casteels K, Elding Larsson H, Haupt F, Hommel A, Jacobs A, Kordonouri O, Lundgren M, Ołtarzewski M, Pfirrmann M, Snape MD, Szypowska A, Todd JA, Vatish M, von dem Berge T, Winkler C, Bonifacio E; GPPAD-POInT Study Group.
Ziegler AG, et al.
Lancet. 2025 Nov 29;406(10519):2564-2576. doi: 10.1016/S0140-6736(25)01726-X. Epub 2025 Nov 11.
Lancet. 2025.
PMID: 41237794
Free article.
Clinical Trial.
BACKGROUND: Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. ...METHODS: In this randomised, controlled, primary prevention trial, genetic screening in seven obstetric and paediatric clinics in Germany, Pol …
BACKGROUND: Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. ...METHODS: …